Tuesday, July 1, 2025 7/1/2025

Cancer Immune Monitoring and Analysis Center

Award Number: U24CA224331
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2017
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Cancer Immune Monitoring and Analysis Center - Summary The critical role of the immune system in effecting anti-tumor responses to traditional and molecularly-targeted therapies is increasingly recognized, such that there is now an explosion of activity in the clinical investigation of immuno-oncology. In parallel, we have gained great advances in our ability to extract useful biologic information from patient material through the development of: (i) high-throughput DNA/RNA sequencing, that has uncovered major genetic determinants of clinically-evident immune responses; (ii) highly multiplexed biological assays, that have revealed the complex interplay between immunity and cancer in relation to therapy; and (iii) advanced computational methods, that have enabled large-scale integrative data analysis. Underlying this activity is a need to identify the critical biomarkers of response and resistance to therapy in each disease and across diseases. With the rapidly evolving clinical and experimental developments in immunotherapy occurring across all major academic centers, the need to build a coordinated infrastructure for data collection, processing and analysis has emerged as a high priority. At Dana-Farber Cancer Institute (DFCI), the Center of Immuno-Oncology (CIO) was established several years ago and is a local hub of translational immuno-oncology activity. As a part of its mission, the CIO supports dedicated translational biomarker laboratories to provide expertise in the analysis of immune correlatives in the service of immuno-oncology trials. Collectively, these resources provide multidisciplinary capabilities supporting both investigator-initiated and externally-sponsored studies ranging from clinical trial design, the performance of well-validated immune monitoring capabilities on patient samples during trials, the interpretation of data from immune monitoring testing, and the development of novel assays based on the scientific questions motivated by individual clinical studies. We propose to expand the laboratory and biostatistical capabilities of the CIO along with those of additional DFCI units as a Cancer Immune Monitoring and Analysis Center (CIMAC). We want to coordinate the efforts of the proposed DFCI-CIMAC with other CIMACs and with the Cancer Immunologic Data Commons (CIDC) to develop the standards for designing studies rich with immune correlatives and informative for candidate biomarkers, to be tested in future trials. Aim 1 focuses on harmonizing the technical aspects of assays offered by the CIMACs; Aim 2 focuses on the assay-specific scoring analyses and reporting of CIMAC offerings. Modeled on our long history of implementing standard and innovative assays to study DFCI phase I/II trials, we describe a process for using `Tier 1' `shovel-ready' assays that we expect as standard components of an immune monitoring tool-kit and `Tier 2' assays that are tailored to the specific needs of a study (Aim 3). Altogether, these efforts fall within the concept and vision of personalized medicine for immuno-oncology because only by the analyses of large well-annotated datasets can we identify links between biology, molecular markers and clinical response.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $1,838,130 )
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	3	6/6/2024	NON-COMPETING CONTINUATION	$1,838,130
2024	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	2/22/2024	NEW	$0
														Subtotal = $1,838,130

Issue Date FY: 2023 ( Subtotal = $1,973,873 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	001	2	8/25/2023	COMPETING CONTINUATION	$0
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	8/10/2023	COMPETING CONTINUATION	$1,973,873
														Subtotal = $1,973,873

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	2/26/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $10,708,495 )
2017	2017	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/25/2017	NEW	$10,708,495
														Subtotal = $10,708,495

Grand Total All Awards = $14,520,498

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cancer Immune Monitoring and Analysis Center

Award Number: U24CA224331

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2017

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer